Ligand Pharma (LGND) Tops Q2 EPS by 60c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $322.75 +1.71%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $37.73 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kosmos Energy (KOS) Misses Q3 EPS by 3c
- Ligand Pharma (LGND) Tops Q3 EPS by 37c ; Offers Guidance
- RBC Capital Downgrades Coles Group Ltd. (COL:AU) (CLEGF) to Sector Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
